Workday CEO, Aneel Bhusri, opened his first Rising keynote since returning to the top job with a confession. He'd wanted to ...

Legal technology is moving from experimentation to enterprise deployment, but with more tools, rising demands and tighter resources, choosing the right technology has become increasingly complex. Join ...

Oracle has sent a force majeure notice to the developer of Project Jupiter, a Stargate data center campus in New Mexico, Bloomberg first reported Thursday. Force majeure clauses, common in energy and ...

HCM Unlocked, a team of more than 200 employees, expands SPG's employee benefits and workforce capabilities with managed HR, payroll, benefits, tax/absence compliance and HCM technology services, ...

Blue Owl says notice does not change financial commitments to multi-year project Blue Owl has about $3 billion in equity, while Oracle pays debt costs, source says Oracle says Project Jupiter remains ...

Workday wins out over SAP SuccessFactors in my 2026 HCM comparison. Compare pricing, HR features, payroll, AI, integrations, ...

Oracle has been named a Leader in the 2026 Gartner® Magic Quadrant™ for HCM Suites for 1,000+ Employee Enterprises. This is the 11th consecutive year Oracle has been named a Leader in the overall ...

A second wave of early-morning termination emails from "Oracle Leadership" reached employees across the United States, India, Canada, Mexico, and other countries today — the same week Oracle disclosed ...

Oracle employees woke up Monday to a brutal email informing them it would be their last day at the tech giant in its latest round of layoffs. The tech giant sent out termination emails at 6 a.m., ...

Oracle's results surpassed consensus on the top and bottom lines. Revenue growth came in at about 30% for the fiscal first quarter and could accelerate this period. In this article Oracle shares moved ...

Nonobstructive hypertrophic cardiomyopathy (HCM) is a common condition that is associated with substantial morbidity and no proven medical therapy. Whether treatment with aficamten, a cardiac myosin ...

There are currently no approved treatments for symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The ACACIA-HCM trial compared the cardiac myosin inhibitor, aficamten, with placebo in ...